Home › Juvenile Myelomonocytic Leukemia
Juvenile Myelomonocytic Leukemia clinical trials recruiting in the U.S.
10 studies for Juvenile Myelomonocytic Leukemia are recruiting participants at sites across the United States.
Cities with the most studies
- Minneapolis, MN4 studies
- Philadelphia, PA4 studies
- St. Louis, MO3 studies
- Seattle, WA3 studies
- Boston, MA3 studies
- Atlanta, GA3 studies
- Indianapolis, IN3 studies
- Ann Arbor, MI3 studies
- Chicago, IL3 studies
- Washington, DC3 studies
- San Francisco, CA3 studies
- Cincinnati, OH3 studies
- Memphis, TN3 studies
- New York City, NY3 studies
By state
- California3 studies
- Colorado3 studies
- District of Columbia3 studies
- Florida3 studies
- Georgia3 studies
- Illinois3 studies
- Indiana3 studies
- Massachusetts3 studies
- Michigan3 studies
- Minnesota4 studies
- Missouri4 studies
- New York3 studies
- Ohio3 studies
- Pennsylvania4 studies
- Tennessee3 studies
- Texas3 studies
- Washington3 studies
Recently updated studies
Therapeutic RSK1 Targeting in Myeloid Malignancies
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 21, 2026 · NCT07379125A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia
RecruitingPhase 1/2
1 Month – 21 Years · All sexes · Updated Sep 4, 2026 · NCT05849662The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
RecruitingPhase 1/2
Up to age 22 · All sexes · Updated Aug 25, 2026 · NCT04726241A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy
RecruitingPhase 1
Ages 1 to 18 · All sexes · Updated Aug 25, 2026 · NCT06247787CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT
Recruiting
Up to age 25 · All sexes · Updated Jul 8, 2026 · NCT03810196Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
RecruitingPhase 2
Up to age 60 · All sexes · Updated Jun 25, 2026 · NCT03314974A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation
RecruitingPhase 1
Ages 12 and older · All sexes · Updated Jun 17, 2026 · NCT04024761Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases
RecruitingPhase 2
6 Months – 39 Years · All sexes · Updated Jun 4, 2026 · NCT05800210HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
RecruitingPhase 1
Up to age 80 · All sexes · Updated May 18, 2026 · NCT03326921MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
RecruitingPhase 2
Up to age 60 · All sexes · Updated Apr 6, 2026 · NCT05735717From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.